COMPANY PROFILE / #2615
ImpriMed
Palo Alto, CAVenture Capital-Backed
OVERVIEW
Developer of a personalized drug response prediction technology designed to offer vet information against lymphoma. The company's technology offers precision medicine techniques to allow veterinary oncologists to find appropriate anticancer drugs by building up a patient-derived database for pet cancer treatment which can be eventually translated into human cancer care, enabling doctors to decide on a final treatment regimen based on a data-driven prediction of response success in each patient body.
已融资34.73
最新估值73.00
员工数44
成立年份2017
公司概况
- Companies
- ImpriMed
- Description
- Developer of a personalized drug response prediction technology designed to offer vet information against lymphoma. The company's technology offers precision medicine techniques to allow veterinary oncologists to find appropriate anticancer drugs by building up a patient-derived database for pet cancer treatment which can be eventually translated into human cancer care, enabling doctors to decide on a final treatment regimen based on a data-driven prediction of response success in each patient body.
- Website
- www.imprimedicine.com
- HQ Location
- Palo Alto, CA
- Year Founded
- 2017
- Keywords
- cancer research platform, drug testing tool, drugs test, medical services, precision medicine, vet pharma, veterinary oncology
- Competitors
- FidoCure
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 34.73
- First Financing Date
- —
- First Financing Size
- —
- First Financing Valuation
- —
- Last Financing Date
- 19-May-2026
- Last Financing Deal Type
- Accelerator/Incubator
- Last Financing Size
- —
- Last Financing Valuation
- —
- Last Financing Status
- Completed
- Last Known Valuation
- 73.00
- Last Known Valuation Date
- 10-Nov-2023
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 89.49
- Valuation Estimate Growth Rate
- 22.59%
- Active Investors
- Bass Investment, Blue Bear Ventures, BonAngels Venture Partners, Byuksan, Draper Associates, Draper Dragon, ES Investor, FuturePlay, Han River Development, HG Initiative, Ignite Innovation, Ironfire Ventures, Korea AI Startup 100, Korea Development Bank, Matter (Consulting Services (B2B)), Mayo Clinic Platform, MedTech Innovator, Murex Partners, Pet Care Innovation, Plug and Play, Samyang Chemical Group, Sazze Partners, SBVA, SK Telecom, StartX (US), Transitions First, Translink Investment
- # Active Investors
- 27
- Acquirers
- —
团队与联系人
- Employees
- 44
- Employee Growth %
- 33.33%
- Employee History
- 2025: 44, 2024: 33, 2023: 40, 2022: 27, 2021: 17
- Primary Contact
- Sungwon Lim
- Primary Contact Title
- Co-Founder, Chief Executive Officer & Board Member
- Primary Contact Email
- sungwon@imprimedicine.com
- Primary Contact Phone
- +1 (650) 521-0165
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- —
- Growth Rate % Change
- —
- Growth Rate Percentile
- —
- Size Multiple
- —
- Size Multiple % Change
- —
- Size Multiple Change
- —
- Size Multiple Percentile
- —
- Majestic Referring Domains
- —
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- —
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 3%
- Success Probability Over Time – 3 Year
- 11%
- Success Probability Over Time – 5 Year
- 23%
记录来源：public.companies · 原始序号 #2615 · 所有字段均按数据库原值展示。